Patents by Inventor Cristina LECCI

Cristina LECCI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel Ferroportin Inhibitors
    Publication number: 20180297991
    Abstract: The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
    Type: Application
    Filed: October 21, 2016
    Publication date: October 18, 2018
    Inventors: Franz Dürrenberger, Wilm Buhr, Susanna Burckhardt, Michael Burgert, Aris Kalogerakis, Stefan Reim, Vania Manolova, Susan Boyce, Christopher John Yarnold, Paula Pena, Jon Shepherd, Cristina Lecci, Richard Jarjes-Pike, John Scott
  • Bicyclic inhibitors of PAD4
    Patent number: 9963448
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: May 8, 2018
    Assignee: Padlock Therapeutics, Inc.
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Michael F. Parker, Edward Beaumont, Lee Bowles, Steve Bromidge, Sophie Cooper, Elise Gadouleau, Laura Gleave, Philip Kerry, Adrian Kotey, Thomas Krulle, Cristina Lecci, Pui Loke, Mirco Meniconi, Nat Monck, Carl North, Jordan Palfrey, Shelley Parrott, Mark Ridgill, Heather Tye
  • Aza-benzimidazole inhibitors of PAD4
    Patent number: 9765093
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: September 19, 2017
    Assignee: Padlock Therapeutics, Inc.
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Laura Gleave, Adrian Kotey, Thomas Krulle, Cristina Lecci, Heather Tye, Ian Wigginton
  • BICYCLIC INHIBITORS OF PAD4
    Publication number: 20170166565
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Application
    Filed: December 9, 2016
    Publication date: June 15, 2017
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Michael F. Parker, Edward Beaumont, Lee Bowles, Steve Bromidge, Sophie Cooper, Elise Gadouleau, Laura Gleave, Philip Kerry, Adrian Kotey, Thomas Krulle, Cristina Lecci, Pui Loke, Mirco Meniconi, Nat Monck, Carl North, Jordan Palfrey, Shelley Parrott, Mark Ridgill, Heather Tye
  • AZA-BENZIMIDAZOLE INHIBITORS OF PAD4
    Publication number: 20170166592
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Application
    Filed: December 9, 2016
    Publication date: June 15, 2017
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Laura Gleave, Adrian Kotey, Thomas Krulle, Cristina Lecci, Heather Tye, Ian Wigginton
  • Benzylic oxindole pyrimidines
    Patent number: 8546443
    Abstract: The present invention encompasses compounds of general formula (I) wherein the groups R5 to R10, A, L1, B, m and p are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: October 1, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Treu, Stephan Karl Zahn, Patricia Amouzegh, Cristina Lecci, Heather Tye
  • BENZYLIC OXINDOLE PYRIMIDINES
    Publication number: 20120329771
    Abstract: The present invention encompasses compounds of general formula (I) wherein the groups R5 to R10, A, L1, B, m and p are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.
    Type: Application
    Filed: December 19, 2011
    Publication date: December 27, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Matthias TREU, Stephan Karl ZAHN, Patricia AMOUZEGH, Cristina LECCI, Heather TYE